Scopa James Paul's Form 4 filing
DICE Therapeutics, Inc. (DICE) · filed Sep 16, 2021
- Accession no.
- 0001209191-21-056526
- Filed
- Sep 16, 2021
- Trade date
- Sep 14-15, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 4 derivative transactions. Open-market purchases total $102.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Scopa James PaulCIK 0001356950 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 15, 2021 | Common Stock | PPurchaseAcquired | +6,000 | $17.00 | +$102,000 | 55,841 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 14, 2021 | Common Stock | AGrant or awardAcquired | +12,096 | $0.00 | $0 | 12,096 | Direct | |
| Sep 14, 2021 | Common Stock | AGrant or awardAcquired | +8,261 | $0.00 | $0 | 8,261 | Direct | |
| Sep 14, 2021 | Common Stock | AGrant or awardAcquired | +8,200 | $0.00 | $0 | 8,200 | Direct | |
| Sep 14, 2021 | Common Stock | AGrant or awardAcquired | +5,600 | $0.00 | $0 | 5,600 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.